Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma

Lancet Oncol. 2010 Nov;11(11):1014-6. doi: 10.1016/S1470-2045(10)70248-5.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Boronic Acids / adverse effects*
  • Bortezomib
  • Gene Expression Profiling
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Humans
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / genetics
  • Neoplasm Staging
  • Peripheral Nervous System Diseases / chemically induced*
  • Peripheral Nervous System Diseases / genetics
  • Polymorphism, Single Nucleotide
  • Pyrazines / adverse effects*
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Vincristine / adverse effects*

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Vincristine
  • Bortezomib